Breaking Finance News

A statement released earlier today by Goldman Sachs about Bank of N.T. Butterfield & Son (CVE:NTB) bumps the target price to $27.00

Goldman Sachs bumped up the target of Bank of N.T. Butterfield & Son (CVE:NTB) to $27.00 reporting a potential upside of 0.05%.

Having a price of $25.61, Bank of N.T. Butterfield & Son (CVE:NTB) traded -6.63% lower on the day. With the last close up 23.21% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. NTB has recorded a 50-day average of $1.42 and a two hundred day average of $1.37. Trade Volume was down over the average, with 47,971 shares of NTB changing hands under the typical 52,173

Recent Performance Chart

Bank of N.T. Butterfield & Son (CVE:NTB)

Bank of N.T. Butterfield & Son has with a one year low of $1.08 and a one year high of $2.02 and has a total market value of $0.

Brief Synopsis About Bank of N.T. Butterfield & Son (CVE:NTB)

Neptune Technologies & Bioressources Inc. is a solution provider of omega-3's and other functional ingredients to branded marketers in the nutraceutical industry, primarily in North America. The Company is engaged in the development, manufacture and commercialization of marine-derived omega-3 fatty acids. The Company's products include Krill-Based Nutraceutical Products, including Neptune Krill Oil (NKO), OCEANO3, Formulations Derived from NKO and Neptune Krill Aquatein (NKA); Other Nutraceutical Products, and Pharmaceutical Product Candidate (CaPre)-Acasti. The Company's NKO is a marine oil extracted from krill (Euphasia superba). NKO consists of phospholipids, which contain omega-3 fatty acids, including eicosapentaenoic acid and docosahexaenoic acid (EPA & DHA), and antioxidants, such as astaxanthin, vitamin A and vitamin E. The Company sells OCEANO3 directly to consumers in Canada through its online platform (, under its brand name.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *